Dementia: Is new drug a major breakthrough?
LMTX slows Alzheimer's progression - but it doesn't work on everyone and experts are urging caution
A new drug appears to slow down the progression of Alzheimer's disease – but only in certain cases.
Some scientists have hailed the results of the trial as a major breakthrough in a field that has seen little advancement in decades, but others are far more sceptical.
What is it and how does it work?
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
LMTX is taken twice a day in tablet form. In the trial, it was used to treat 891 patients with mild to moderate Alzheimer's for 18 months, with the results presented at a conference in Toronto, Canada.
It is the first time a major drug trial has targeted tau tangles – abnormal clumps of protein that disrupt brain function – instead of beta-amyloid, a different type of protein that forms plaques as it accumulates in the brain, the New Scientist reports.
"The success of the LMTX trial suggests that tau tangles might be the main cause of Alzheimer's symptoms," it says.
How successful is it?
Overall, the trial was a flop as there appeared to be no benefit to taking LMTX, says the BBC's health and science correspondent, James Gallagher.
"However, an analysis on just the 15 per cent of the patients who had not already been taking drugs to help manage their symptoms showed a benefit," he adds. "In this tiny subset of patients, tests showed thinking power was maintained and MRI scans found the death of brain cells was reduced."
Claude Wischik, the co-founder of TauRx Pharmaceuticals, which developed the drug, said the results were unprecedented. "On the whole, [it] slowed progression by about 80 per cent," he says.
Though further testing is needed, LMTX has helped people get back to their daily lives, he says: "A wife of a patient told me her husband suddenly got up and fixed the garden fence, which he'd needed to do for years."
What has the reaction been?
The discovery was hailed by many, with the US Alzheimer's Association describing it as "a significant event" in the history of dementia research.
"In a field that has been plagued by consistent failures of novel drug candidates in late-stage clinical trials and where there has been no practical therapeutic advance for over a decade, I am excited," said Dr Serge Gauthier, the director of the Alzheimer's Disease Research Unit at McGill University, Canada.
Others, however, have urged caution. Alzheimer's Research UK's Dr David Reynolds said he was concerned LMTX appeared not to work alongside other medications.
"The data suggests it is slowing down the disease, but the important caveat is these small numbers," he said.
"It is encouraging, but we need more data and will have to run a study with it as just a monotherapy [on its own]," he added. "It will still be years from reaching patients, even assuming it works."
Dr Rachelle Doody, the director of the Alzheimer's disease and Memory Disorders Center at Baylor College of Medicine in Texas, was even more pessimistic. "To present it to the public now as a promising approach seems unjustified," she told the New York Times.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
-
Will Donald Trump wreck the Brexit deal?
Today's Big Question President-elect's victory could help UK's reset with the EU, but a free-trade agreement with the US to dodge his threatened tariffs could hinder it
By Harriet Marsden, The Week UK Published
-
Marine Le Pen's fake jobs trial
The Explainer The far-right French leader could face a fine, jail time, and a five-year ban from public office if found guilty of embezzlement
By Abby Wilson Published
-
How to earn extra cash for Christmas
The Explainer The holiday season can be expensive but there are ways to bolster your festive finances
By Marc Shoffman, The Week UK Published
-
Has the Taliban banned women from speaking?
Today's Big Question 'Rambling' message about 'bizarre' restriction joins series of recent decrees that amount to silencing of Afghanistan's women
By Harriet Marsden, The Week UK Published
-
Cuba's energy crisis
The Explainer Already beset by a host of issues, the island nation is struggling with nationwide blackouts
By Rebekah Evans, The Week UK Published
-
Putin's fixation with shamans
Under the Radar Secretive Russian leader, said to be fascinated with occult and pagan rituals, allegedly asked for blessing over nuclear weapons
By Harriet Marsden, The Week UK Published
-
Chimpanzees are dying of human diseases
Under the radar Great apes are vulnerable to human pathogens thanks to genetic similarity, increased contact and no immunity
By Harriet Marsden, The Week UK Published
-
Deaths of Jesse Baird and Luke Davies hang over Sydney's Mardi Gras
The Explainer Police officer, the former partner of TV presenter victim, charged with two counts of murder after turning himself in
By Austin Chen, The Week UK Published
-
Quiz of The Week: 24 February - 1 March
Puzzles and Quizzes Have you been paying attention to The Week's news?
By Sorcha Bradley, The Week UK Published
-
Will mounting discontent affect Iran election?
Today's Big Question Low turnout is expected in poll seen as crucial test for Tehran's leadership
By Sorcha Bradley, The Week UK Published
-
Sweden clears final NATO hurdle with Hungary vote
Speed Read Hungary's parliament overwhelmingly approved Sweden's accession to NATO
By Peter Weber, The Week US Published